Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTER-G-001: anlotinib plus first-line chemotherapy for gastrointestinal tumors with unresectable liver metastases
ChiCTR2100050872Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in colorectal cancer (CRC), Esophageal Squamous Cell Carcinoma (ESCC) and gastrointestinal cancer (3 cohorts), sponsored by Ruijin Hospital. Primary endpoint: Objective response rate. Started Sep 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
colorectal cancer (CRC)Esophageal Squamous Cell Carcinoma (ESCC)gastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2100050872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050872.